Stereotactic Body Radiation Therapy for Nonspine Bone Metastases: International Practice Patterns to Guide Treatment Planning.


Journal

Practical radiation oncology
ISSN: 1879-8519
Titre abrégé: Pract Radiat Oncol
Pays: United States
ID NLM: 101558279

Informations de publication

Date de publication:
Historique:
received: 05 12 2019
revised: 04 02 2020
accepted: 06 02 2020
pubmed: 17 3 2020
medline: 7 8 2021
entrez: 16 3 2020
Statut: ppublish

Résumé

Stereotactic body radiation therapy (SBRT) is increasingly used for nonspine bone metastases (NSBM); however, there are limited data informing treatment planning. We surveyed international experts to better understand worldwide practice patterns in delivering NSBM-SBRT. Nine international radiation oncologists were invited to participate based on demonstrated expertise with NSBM-SBRT. Experts were sent gross tumor volume contours and planning computed tomography and magnetic resonance images for 11 NSBM cases that covered a range of bony sites, including metastases to long bones (femur, humerus), pelvic bones (ilium, ischium, acetabulum, pubic symphysis), and thoracic bones (rib, sternum, scapula, clavicle). Experts were surveyed regarding treatment planning decisions and dose-fractionation selection. Descriptive analysis was conducted on the survey data. All experts participated and completed the survey. Most (56%) routinely fused magnetic resonance imaging with planning computed tomography imaging for target delineation. Dose fractionation schedules included single-fraction (18-24 Gy/1), 2 fractions (24 Gy/2), 3 fractions (28-30 Gy/3), 5 fractions (30-50 Gy/5), and 10 fractions (42-50 Gy/10). Although doses varied considerably, all had a biological equivalent dose of ≤100 Gy Significant heterogeneity exists worldwide in radiation technique and dose-fractionation for NSBM-SBRT, which supports the need for consensus guidelines to inform practice and trial design. Nonetheless, these data demonstrate expert agreement on selecting dose schedules with a biologically effective dose ≤100 Gy

Identifiants

pubmed: 32171852
pii: S1879-8500(20)30056-4
doi: 10.1016/j.prro.2020.02.011
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e452-e460

Informations de copyright

Copyright © 2020 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Auteurs

Timothy K Nguyen (TK)

Department of Radiation Oncology, London Health Sciences Centre, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. Electronic address: Timothy.Nguyen@lhsc.on.ca.

Arjun Sahgal (A)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Roi Dagan (R)

Department of Radiation Oncology, University of Florida Health Proton Therapy Institute, Jacksonville, Florida.

Wietse Eppinga (W)

Department of Radiation Oncology, University Medical Centre, Utrecht, The Netherlands.

Matthias Guckenberger (M)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Jin Ho Kim (JH)

Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea.

Simon S Lo (SS)

Department of Radiation Oncology, University of Washington, Seattle, Washington.

Kristin J Redmond (KJ)

Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University, Baltimore, Maryland.

Shankar Siva (S)

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Bradley J Stish (BJ)

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.

Chia-Lin Tseng (CL)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH